RGC-32, or Response Gene to Complement 32, plays a pivotal role in mediating cellular responses following complement activation. Acting as a regulator of the cell cycle, RGC-32 is implicated in ...
Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from Novo Holdings, Bioqube Ventures, and Korys, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results